Stanley Plotkin - Dynavax Technologies Independent Director
| DVAX Stock | USD 11.76 0.08 0.68% |
Director
Dr. Stanley A. Plotkin, M.D., is no longer Independent Director of Dynavax Technologies Corporation effective on May 31, 2018. Dr. Plotkin is Emeritus Professor of the University of Pennsylvania. Until 1991, he was Professor of Pediatrics and Microbiology at the University of Pennsylvania and Professor of Virology at the Wistar Institute and, at the same time, Director of Infectious Diseases and Senior Physician at the Childrens Hospital of Philadelphia. In 1991, Dr. Plotkin left the University to join the vaccine manufacturer PasteurMrieuxConnaught, where for seven years he was Medical and Scientific Director, based at MarneslaCoquette, outside Paris. Until 2009, he was an Executive Advisor to Sanofi Pasteur. The Board believes that Dr. Plotkins significant experience in development and manufacturing of vaccines provides significant insights for the strategy of the Company with respect to key technical and operational issues in vaccine development and qualifies him to be nominated as a director. Dr. Plotkins career included an nternship at Cleveland Metropolitan General Hospital, residency in pediatrics at the Childrens Hospital of Philadelphia and the Hospital for Sick Children in London and three years in the Epidemic Intelligence Service of the Centers for Disease Control of the U.S. Public Health Service. He was chairman of the Infectious Diseases Committee and the AIDS Task Force of the American Academy of Pediatrics, liaison member of the Advisory Committee on Immunization Practices and Chairman of the Microbiology and Infectious Diseases Research Committee of the National Institutes of Health. since 2005.
| Age | 83 |
| Tenure | 19 years |
| Address | 2100 Powell Street, EmeryVille, CA, United States, 94608 |
| Phone | 510 848 5100 |
| Web | https://www.dynavax.com |
Dynavax Technologies Management Efficiency
The company has return on total asset (ROA) of (0.0192) % which means that it has lost $0.0192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0106) %, meaning that it created substantial loss on money invested by shareholders. Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.0067 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, Dynavax Technologies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 19.9 M in 2024, whereas Other Assets are likely to drop slightly above 3 M in 2024.Similar Executives
| Found 5 records | DIRECTOR Age | ||
| Alan Howarth | Terns Pharmaceuticals | 69 | |
| Albert Sisto | Terns Pharmaceuticals | 63 | |
| Angus Forrest | Terns Pharmaceuticals | N/A | |
| Bruce Leith | Terns Pharmaceuticals | N/A | |
| Sarah Payne | Terns Pharmaceuticals | 41 | |
Management Performance
| Return On Equity | -0.0106 | ||||
| Return On Asset | -0.0192 |
Dynavax Technologies Leadership Team
Elected by the shareholders, the Dynavax Technologies' board of directors comprises two types of representatives: Dynavax Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dynavax. The board's role is to monitor Dynavax Technologies' management team and ensure that shareholders' interests are well served. Dynavax Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dynavax Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Arnold Oronsky, Independent Chairman of the Board | ||
| Francis Cano, Independent Director | ||
| Daniel Kisner, Independent Director | ||
| Dennis Carson, Independent Director | ||
| Robert Janssen, Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs | ||
| Eddie Gray, CEO and Director | ||
| Peggy Phillips, Independent Director | ||
| Nicole Arndt, Sr Relations | ||
| Laura Brege, Director | ||
| David Johnson, Chief Accounting Officer, Vice President | ||
| Andrew Hack, Director | ||
| John Slebir, Senior Counsel | ||
| Jeff Coon, CHRO Administration | ||
| Meg Smith, VP Operations | ||
| Todd Lopeman, Senior Operations | ||
| Stanley Plotkin, Independent Director | ||
| Dan Kisner, Independent Director | ||
| Riccardo Manetti, Business President | ||
| Eric Frings, Site VP | ||
| Natale Ricciardi, Director | ||
| David Novack, Sr. VP of Operations and Quality | ||
| Donn Casale, Chief Officer | ||
| Kelly MacDonald, Senior CFO | ||
| Paul Cox, VP Communications | ||
| Dong Yu, Senior Research | ||
| Ryan Spencer, Interim Co-President Co-Principal Executive Officer | ||
| Robert Coffman, Chief Scientific Officer and Sr. VP | ||
| Justin Burgess, Principal Controller | ||
| Michael Ostrach, Principal Financial Officer, Vice President General Counsel, Chief Business Officer |
Dynavax Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dynavax Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0106 | ||||
| Return On Asset | -0.0192 | ||||
| Profit Margin | (0.03) % | ||||
| Operating Margin | (0.12) % | ||||
| Current Valuation | 1.01 B | ||||
| Shares Outstanding | 130.86 M | ||||
| Shares Owned By Insiders | 0.31 % | ||||
| Shares Owned By Institutions | 98.00 % | ||||
| Number Of Shares Shorted | 18.54 M | ||||
| Price To Earning | 6.95 X |
Pair Trading with Dynavax Technologies
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dynavax Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dynavax Technologies will appreciate offsetting losses from the drop in the long position's value.Moving against Dynavax Stock
| 0.66 | XFOR | X4 Pharmaceuticals Buyout Trend | PairCorr |
| 0.66 | LLY | Eli Lilly Earnings Call This Week | PairCorr |
| 0.66 | NRSNW | NeuroSense Therapeutics | PairCorr |
| 0.53 | ELEV | Elevation Oncology Earnings Call This Week | PairCorr |
| 0.53 | ACB | Aurora Cannabis Trending | PairCorr |
The ability to find closely correlated positions to Dynavax Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dynavax Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dynavax Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dynavax Technologies to buy it.
The correlation of Dynavax Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dynavax Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dynavax Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dynavax Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dynavax Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. For more information on how to buy Dynavax Stock please use our How to Invest in Dynavax Technologies guide.Note that the Dynavax Technologies information on this page should be used as a complementary analysis to other Dynavax Technologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Complementary Tools for Dynavax Stock analysis
When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities |
Is Dynavax Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dynavax Technologies. If investors know Dynavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dynavax Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.77) | Earnings Share (0.05) | Revenue Per Share 1.804 | Quarterly Revenue Growth (0.70) | Return On Assets (0.02) |
The market value of Dynavax Technologies is measured differently than its book value, which is the value of Dynavax that is recorded on the company's balance sheet. Investors also form their own opinion of Dynavax Technologies' value that differs from its market value or its book value, called intrinsic value, which is Dynavax Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dynavax Technologies' market value can be influenced by many factors that don't directly affect Dynavax Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dynavax Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dynavax Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dynavax Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.